Trade Aligos Therapeutics, Inc. - ALGS CFD
Add to favourite- Summary
- Historical Data
Spread | 0.3284 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 13.7058 |
Open | 14.0258 |
1-Year Change | 1658.5% |
Day's Range | 14.0258 - 14.7658 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 17, 2024 | 13.7058 | -0.4600 | -3.25% | 14.1658 | 14.8658 | 13.5458 |
Sep 16, 2024 | 14.2158 | 0.1800 | 1.28% | 14.0358 | 14.7958 | 14.0258 |
Sep 13, 2024 | 14.3258 | 0.6500 | 4.75% | 13.6758 | 14.9158 | 13.6758 |
Sep 12, 2024 | 13.7358 | -0.5600 | -3.92% | 14.2958 | 16.2658 | 13.0958 |
Sep 11, 2024 | 13.7258 | -0.0400 | -0.29% | 13.7658 | 14.5758 | 13.2358 |
Sep 10, 2024 | 13.5980 | -4.4000 | -24.45% | 17.9980 | 17.9980 | 12.7280 |
Sep 9, 2024 | 18.9980 | 6.7900 | 55.62% | 12.2080 | 19.2880 | 12.0780 |
Sep 6, 2024 | 12.0980 | 0.6200 | 5.40% | 11.4780 | 12.4380 | 11.2780 |
Sep 5, 2024 | 11.8380 | 0.4400 | 3.86% | 11.3980 | 11.9080 | 11.1980 |
Sep 4, 2024 | 11.5480 | -0.4400 | -3.67% | 11.9880 | 12.0480 | 11.4780 |
Sep 3, 2024 | 11.6980 | -0.8000 | -6.40% | 12.4980 | 12.4980 | 11.2980 |
Aug 30, 2024 | 12.5080 | -0.2700 | -2.11% | 12.7780 | 12.9080 | 12.3880 |
Aug 29, 2024 | 13.0480 | 0.2400 | 1.87% | 12.8080 | 13.6980 | 12.7780 |
Aug 28, 2024 | 12.7980 | 0.0000 | 0.00% | 12.7980 | 13.0980 | 12.7480 |
Aug 27, 2024 | 13.1280 | -0.0100 | -0.08% | 13.1380 | 13.3480 | 12.4480 |
Aug 26, 2024 | 13.3180 | -0.2400 | -1.77% | 13.5580 | 13.6780 | 13.0980 |
Aug 23, 2024 | 13.7080 | 0.2100 | 1.56% | 13.4980 | 13.7780 | 13.4980 |
Aug 22, 2024 | 13.6980 | 0.0000 | 0.00% | 13.6980 | 14.0980 | 13.1280 |
Aug 21, 2024 | 13.7380 | -0.1600 | -1.15% | 13.8980 | 14.1880 | 13.3480 |
Aug 20, 2024 | 14.2380 | 0.2300 | 1.64% | 14.0080 | 14.3780 | 13.8980 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Aligos Therapeutics, Inc. Company profile
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. It uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. It is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). It developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The Company's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Aligos Therapeutics Inc revenues increased from $0K to $4.4M. Net loss increased 18% to $128.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 12% to $88.3M (expense), Stock-based Compensation in R&D increase from $1M to $7.6M (expense).
Industry: | Biotechnology & Medical Research (NEC) |
One Corporate Dr., 2Nd Floor
2nd Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Bank of Japan Preview
The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.
09:40, 17 September 2024FOMC Decision Preview
As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.
09:48, 16 September 2024ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com